Logo

NAMS

NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V. • NASDAQ
$41.30 ▼ -0.36% (-0.15)
Market Cap $4.68 B
52w High $42.00
52w Low $14.06
Dividend Yield 0%
P/E -20.25
Volume 308.04K
Outstanding Shares 113.32M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $348K ▼ $55.491M ▲ $-72.005M ▼ -20.691K% ▼ $-0.61 ▼ $-71.941M ▼
Q2-2025 $19.145M ▲ $54.78M ▼ $-17.364M ▲ -90.697% ▲ $-0.15 ▲ $-35.59M ▲
Q1-2025 $2.978M ▼ $71.903M ▲ $-39.527M ▲ -1.327K% ▼ $-0.34 ▲ $-68.873M ▲
Q4-2024 $12.772M ▼ $56.001M ▲ $-92.177M ▼ -721.712% ▼ $-0.98 ▼ $-111.693M ▼
Q3-2024 $29.111M $54.114M $-16.647M -57.185% $-0.18 $-23.84M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $702.946M ▼ $786.427M ▼ $58.357M ▲ $728.07M ▼
Q2-2025 $739.162M ▼ $815.112M ▼ $36.615M ▼ $778.497M ▲
Q1-2025 $808.477M ▼ $818.413M ▼ $41.05M ▼ $777.363M ▲
Q4-2024 $834.19M ▲ $864.62M ▲ $107.12M ▲ $757.5M ▲
Q3-2024 $422.729M $439.191M $60.329M $378.862M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $39.527M ▲ $-32.769M ▲ $2.506M ▲ $5.892M ▲ $-24.149M ▲ $-32.811M ▲
Q2-2025 $0 ▲ $-37.671M ▼ $-159.136M ▼ $3.425M ▼ $-184.556M ▼ $-37.759M ▼
Q1-2025 $-39.527M ▲ $-36.468M ▲ $2.855M ▲ $6.519M ▼ $-23.323M ▼ $-36.484M ▲
Q4-2024 $-92.177M ▼ $-37.481M ▼ $-62.179M ▼ $456.611M ▲ $349.014M ▲ $-37.484M ▼
Q3-2024 $-16.647M $-12.502M $-75K $58K $-7.979M $-12.577M

Revenue by Products

Product Q2-2023
License Revenue
License Revenue
 $0 ▲

Five-Year Company Overview

Income Statement

Income Statement NewAmsterdam is still very much a development-stage biotech company. Revenue so far is tiny and not a driver of results; the story is dominated by research and operating costs. Losses have been consistent over the past several years and have recently widened as the company ramps up late-stage trials. This pattern is typical for a clinical‑stage biotech: expenses rise ahead of any meaningful product sales. The key question over time will be whether future trial outcomes and potential approvals can eventually turn those recurring losses into a more sustainable earnings profile.

Balance Sheet

Balance Sheet The balance sheet is simple and relatively clean. Most assets are held in cash or cash‑like instruments, with very little in the way of physical assets. The company has essentially no financial debt, which lowers balance sheet risk but also means it relies heavily on equity funding and potentially future partnerships or milestones. Equity has grown as the company raised capital, giving it a buffer to support ongoing trials. Overall, this looks like a cash‑rich, low‑leverage balance sheet that is designed to support multi‑year R&D, but it will need to be refreshed over time if losses continue.

Cash Flow

Cash Flow Cash flow reflects a classic biotech burn profile. The company spends more cash on operations than it brings in, so operating and free cash flow are negative. There is effectively no capital spending, so cash use is driven almost entirely by clinical and corporate costs. There was a brief period of slightly positive operating cash flow in the past, likely due to one‑off items or working capital movements, but the core trend is cash outflow. The key issue for stakeholders is how long the current cash reserves can fund the ongoing burn and how that might change as trials progress or if partnership or milestone cash comes in.

Competitive Edge

Competitive Edge NewAmsterdam’s competitive stance centers on a single lead drug, obicetrapib, in the cholesterol‑lowering and cardiovascular risk space. Its main competitive strengths are: a differentiated mechanism within an established drug class, promising clinical data so far, convenient once‑daily oral dosing versus injectable competitors, and long patent protection that could support many years of exclusivity if the drug is approved. At the same time, the company faces large, well‑funded rivals developing other oral cholesterol‑lowering drugs and newer genetic medicines. Its market position will ultimately depend on how obicetrapib’s efficacy, safety, convenience, and cost compare in real‑world use against PCSK9 therapies, statins, and other emerging agents.

Innovation and R&D

Innovation and R&D The company is highly focused on innovation around a single core asset. Obicetrapib is being pushed aggressively through late‑stage cardiovascular trials and is also being explored for Alzheimer’s disease, where early signals are scientifically interesting but still uncertain. This concentrated R&D strategy offers clear focus and potentially strong leverage if the drug succeeds, but it also creates dependence on one main product. The patent estate around obicetrapib appears strong and long‑dated, which is important for capturing value if the clinical program delivers. Management experience in cardiovascular drug development is an additional intangible R&D asset that may help with trial design, regulatory interactions, and eventual commercialization planning.

Summary

NewAmsterdam is a classic high‑risk, high‑potential clinical‑stage biotech: minimal current revenue, steady and rising losses, but a large scientific and commercial opportunity if its lead drug succeeds. Financially, the company is running a controlled but meaningful cash burn funded by a solid cash balance and a debt‑light capital structure. Strategically, its fortunes are tied primarily to obicetrapib, which has an attractive profile on paper—oral dosing, positive early data, and strong patent protection—but faces intense competition and the usual clinical and regulatory uncertainties. The upside case rests on successful late‑stage cardiovascular and potentially Alzheimer’s results; the downside risk stems from concentration in a single program and ongoing cash needs in the absence of commercial products.

NEWS

November 25, 2025 · 8:00 AM UTC

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

Read more

November 7, 2025 · 4:01 PM UTC

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 5, 2025 · 8:00 AM UTC

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Read more

October 30, 2025 · 8:00 AM UTC

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

Read more

October 16, 2025 · 8:45 AM UTC

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

Read more